Upcoming Events for Urologists and Oncologists - UroToday
Oct 2, 2024 · UroToday Home. Calendar. Upcoming Events. September 29-October 2, 2024. 2024 American Society for Radiation Oncology (ASTRO) 66th Annual Meeting. ASTRO is a professional association in radiation oncology that is dedicated to improving patient care through professional education and training, support for clinical practice and health policy ...
2024 International Bladder Cancer Network (IBCN)
IBCN 2024: The Value of mpMRI to Assist in Decision Making in Muscle Invasive Bladder Cancer. IBCN 2024: TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Patients with BCG Unresponsive High-Risk NMIBC: Results from SunRISe-1. IBCN 2024: TAR-200 Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients ...
41st World Congress of Endourology and Uro-Technology
WCET 2024: Bladder Transplantation: Preclinical Work in Preparation for First-in-Human Case. 1. 2. Were you unable to attend 41st World Congress of Endourology and Uro-Technology? Get all of the groundbreaking research, new guidelines, and the latest advances in …
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC
Sep 24, 2024 · Oliver Sartor interviews Bertrand Tombal about the PEACE-3 trial. The study investigates the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer. Dr. Tombal discusses the trial design, results, and implications. The study demonstrates significant improvements in radiographic progression-free survival...
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
According to the EAU-ESTRO-SIOG 2018 guidelines, the biochemical disease-free survival for Gleason 6 prostate cancer at 5 years ranges from 71-93% and at 10 years from 65-85%. However, there is a lack of studies evaluating salvage therapies for locally recurrent prostate cancer after low-dose-rate brachytherapy.
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role …
Sep 15, 2024 · Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile...
ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for
ASCO GU 2024, CheckMate 214 trial, nivolumab, ipilimumab, nivolumab plus ipilimumab, renal cell carcinoma (RCC), checkpoint inhibitor combination therapy.
ASCO GU 2024 - UroToday
ASCO GU 2024: A Randomized, Non-Comparative, Phase II Multicenter Trial of Short-Term Darolutamide Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-Risk Prostate Cancer: DARIUS (AFU-GETUG P15) ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS ...
AMBASSADOR Trial: Extended Follow-up on Adjuvant …
September 15, 2024. Andrea Apolo discusses extended follow-up data from the AMBASSADOR trial. This phase 3 study evaluates adjuvant pembrolizumab versus observation in high-risk muscle-invasive urothelial carcinoma. With 45-month follow-up, pembrolizumab demonstrates significant improvement in disease-free survival (29.6 vs 14.2 months).
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in …
Oct 11, 2024 · Shilpa Gupta interviews Thomas Powles about the NIAGARA study, which examines perioperative chemoimmunotherapy in muscle-invasive bladder cancer. Dr. Powles discusses the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in event-free and overall survival. He emphasizes the study's practice-changing potential, noting ...